<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="; font-style : italic;} Immunol LettImmunol LettImmunology Letters0165-24781879-0542European Federation of" exact="Immunological" post="Societies. Published by Elsevier B.V. pmcid: 7524442S0165-2478(20)30386-2 doi: 10.1016/j.imlet.2020.09.007"/>
 <result pre="pmc-release: 2020-9-9ppub: 2020-12epub: 2020-9-92283844received: 2020-7-8rev-recd: 2020-9-10accepted: 2020-9-22(C) European Federation of" exact="Immunological" post="Societies, 2020Since January 2020 Elsevier has created a COVID-19"/>
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="to personalized approach. Abstract Cytokine storm is a form of" exact="uncontrolled" post="systemic inflammatory reaction activated by a variety of factors"/>
 <result pre="personalized approach. Abstract Cytokine storm is a form of uncontrolled" exact="systemic" post="inflammatory reaction activated by a variety of factors and"/>
 <result pre="to patientâ€™s death. Triggers that start the reaction are infection," exact="systemic" post="diseases and rarely anaphylaxis. Cytokine storm is frequently mentioned"/>
 <result pre="of treatment is imperative. The most widely used molecule for" exact="systemic" post="treatment remains tocilizumab. Except for anti IL-6 treatment, contemporary"/>
 <result pre="to more personalized medicine approaches. Keywords Cytokine storm Cytokine release" exact="syndrome" post="Treatment 1 Introduction Although to date, â€œcytokine stormâ€� is"/>
 <result pre="A recent PubMed search for cytokine storm or cytokine release" exact="syndrome" post="yielded 1102 and 1817 hits respectively; over 100 articles/year"/>
 <result pre="100 articles/year were within the past five years. Cytokine release" exact="syndrome" post="(CRS) or â€œcytokine stormâ€� is a form of uncontrolled"/>
 <result pre="release syndrome (CRS) or â€œcytokine stormâ€� is a form of" exact="uncontrolled" post="systemic inflammatory reaction that can be triggered by a"/>
 <result pre="syndrome (CRS) or â€œcytokine stormâ€� is a form of uncontrolled" exact="systemic" post="inflammatory reaction that can be triggered by a variety"/>
 <result pre="of massive immune activation such as severe courses of some" exact="systemic" post="diseases (RA, SLE), rarely anaphylaxis. It can be frequently"/>
 <result pre="CRS may occur following immunization against rubella, human papillomavirus, or" exact="hepatitis" post="B [3]. The term â€œcytokine release syndromeâ€� appeared in"/>
 <result pre="1975 observed that by administering polyclonal antibodies the possibility of" exact="systemic" post="anaphylactic reactions and other side effects may be present"/>
 <result pre="above, cytokine storm is also a proposed pathomechanism of severe" exact="viral" post="infections due to massive T cell stimulation. It is"/>
 <result pre="cytokine storm is also a proposed pathomechanism of severe viral" exact="infections" post="due to massive T cell stimulation. It is supposed"/>
 <result pre="since Spanish flu in 1919 through dengue, Ebola to corona" exact="virus infection" post="in 2020 [17]. CRS has been observed also in"/>
 <result pre="Spanish flu in 1919 through dengue, Ebola to corona virus" exact="infection" post="in 2020 [17]. CRS has been observed also in"/>
 <result pre="CRS has been observed also in surgical patients with severe" exact="bacterial infections" post="or in patients with inhalation injury [18]. Such broad"/>
 <result pre="has been observed also in surgical patients with severe bacterial" exact="infections" post="or in patients with inhalation injury [18]. Such broad"/>
 <result pre="capillary leakage, tachycardia, tachypnea, hemophagocytic lymphohistiocytosis/macrophage activation syndrome, organ toxicity," exact="pulmonary" post="edema, pneumonitis, and renal insuï¬ƒciency support the basic scientific"/>
 <result pre="collateral damage to surrounding cells can be catastrophic, resulting in" exact="septic shock," post="multiple organ dysfunction, immunosuppression and even death [21]. If"/>
 <result pre="regulated, regulatory mechanisms prevent the body from being damaged by" exact="systemic" post="inflammation caused by sudden activation of cytokine release. Such"/>
 <result pre="are scarce [23]. Even if all forms of cytokine release" exact="syndrome" post="induced by environmental or host factors arrive at their"/>
 <result pre="increased ferritin level, NK dysfunction, and hemophagocytosis [19]. Although the" exact="primary" post="cause of CRS is crucial to understand for restoring"/>
 <result pre="in a view of causes, course and treatment. (HLH -" exact="hemophagocytic lymphohistiocytosis," post="MAS - macrophage activation syndrome, SIRS - systemic inflammatory"/>
 <result pre="- hemophagocytic lymphohistiocytosis, MAS - macrophage activation syndrome, SIRS -" exact="systemic" post="inflammatory response syndrome, NAC â€&quot; N-acetylcysteine). Clinical picture of"/>
 <result pre="web portal â€œClinicalTrials.govâ€� 27 studies under key words cytokine release" exact="syndrome" post="and 32 studies under cytokine storm were analyzed (last"/>
 <result pre="Study title Status Identification number Location Phase* Cytokine Adsorption in" exact="Severe" post="COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation (CYCOV) R NCT04324528"/>
 <result pre="Status Identification number Location Phase* Cytokine Adsorption in Severe COVID-19" exact="Pneumonia" post="Requiring Extracorporeal Membrane Oxygenation (CYCOV) R NCT04324528 Freiburg, Germany"/>
 <result pre="(CYCOV) R NCT04324528 Freiburg, Germany Cytokine Adsorption in Patients With" exact="Severe" post="COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation (CYCOV-II) IP NCT04385771"/>
 <result pre="NCT04324528 Freiburg, Germany Cytokine Adsorption in Patients With Severe COVID-19" exact="Pneumonia" post="Requiring Extracorporeal Membrane Oxygenation (CYCOV-II) IP NCT04385771 Freiburg, Germany"/>
 <result pre="Study C NCT02288975 Szeged, Hungary Cytokine Adsorption in Post-cardiac Arrest" exact="Syndrome" post="in Patients Requiring Extracorporeal Cardiopulmonary Resuscitation (CYTER) R NCT03685383"/>
 <result pre="Cytokine Adsorption as Additive Treatment of CAR-T Associated Cytokine Release" exact="Syndrome" post="(CRS) (CYTORELEASE) IP NCT04048434 Hannover, Germany Effects of Endotoxin"/>
 <result pre="Germany Effects of Endotoxin Absorption and Cytokine Removal Hemofilter on" exact="Severe" post="Septic Shock R NCT03974386 Taipei, Taiwan Safety and Efficacy"/>
 <result pre="of Endotoxin Absorption and Cytokine Removal Hemofilter on Severe Septic" exact="Shock" post="R NCT03974386 Taipei, Taiwan Safety and Efficacy of Hyperbaric"/>
 <result pre="and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related" exact="Pneumonia" post="(TOSCA) R NCT04332913 L'Aquila, Italy Tocilizumab for Cytokine Release"/>
 <result pre="Pneumonia (TOSCA) R NCT04332913 L'Aquila, Italy Tocilizumab for Cytokine Release" exact="Syndrome" post="Prophylaxis in Haploidentical Transplantation R NCT03533101 Monterrey, Mexico **"/>
 <result pre="of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release" exact="Syndrome" post="IP NCT02906371 Philadelphia (PA), US Phase 3 Randomized, Double-blind,"/>
 <result pre="(62 centers) worldwide Phase 3 Ruxolitinib for the Treatment of" exact="Acute" post="Respiratory Distress Syndrome in Patients With COVID-19 Infection (RESPIRE)"/>
 <result pre="centers) worldwide Phase 3 Ruxolitinib for the Treatment of Acute" exact="Respiratory" post="Distress Syndrome in Patients With COVID-19 Infection (RESPIRE) IP"/>
 <result pre="Phase 3 Ruxolitinib for the Treatment of Acute Respiratory Distress" exact="Syndrome" post="in Patients With COVID-19 Infection (RESPIRE) IP NCT04361903 Pisa,"/>
 <result pre="Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19" exact="Infection" post="(RESPIRE) IP NCT04361903 Pisa, Italy Treatment of SARS Caused"/>
 <result pre="Effects of Free Fatty Acids and 3-hydroxybutyrate on Protein, Glucose," exact="Lipid Metabolism" post="and Intracellular Signals C NCT01752348 Aarhus C, Denmark Prevention"/>
 <result pre="of Free Fatty Acids and 3-hydroxybutyrate on Protein, Glucose, Lipid" exact="Metabolism" post="and Intracellular Signals C NCT01752348 Aarhus C, Denmark Prevention"/>
 <result pre="C, Denmark Prevention and Treatment With Calcifediol of COVID-19 Induced" exact="Acute" post="Respiratory Syndrome (COVIDIOL) IP NCT04366908 CÃ³rdoba, Spain Phase 2"/>
 <result pre="Denmark Prevention and Treatment With Calcifediol of COVID-19 Induced Acute" exact="Respiratory" post="Syndrome (COVIDIOL) IP NCT04366908 CÃ³rdoba, Spain Phase 2 The"/>
 <result pre="Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory" exact="Syndrome" post="(COVIDIOL) IP NCT04366908 CÃ³rdoba, Spain Phase 2 The Effect"/>
 <result pre="Amman, Jordan A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in" exact="Severe" post="Coronavirus Disease 2019 (COVID-19) Patients (PRANA) R NCT04458298 Multicentric"/>
 <result pre="A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus" exact="Disease" post="2019 (COVID-19) Patients (PRANA) R NCT04458298 Multicentric (5 centers),"/>
 <result pre="â€&quot; active, but recruitment interrupted in 2018, *** â€&quot; only" exact="Swedish" post="center started to recruit, IP â€&quot; in preparation, R"/>
 <result pre="management caused by SARS-CoV-2 (NCT04324528, NCT04385771), in severe burns (NCT04195126)," exact="septic shock" post="(NCT02288975), cardiac arrest (NCT03685383) and after CAR-T cell therapy"/>
 <result pre="SARS-CoV-2 (NCT04324528, NCT04385771), in severe burns (NCT04195126), septic shock (NCT02288975)," exact="cardiac arrest" post="(NCT03685383) and after CAR-T cell therapy (NCT04048434). Haemoadsorbtion can"/>
 <result pre="and anti-inflammatory cytokines and thus improve the course of the" exact="disease" post="and the outcome of patients. One of them (NCT03974386)"/>
 <result pre="to establish influence of environmentally induced inflammation caused by gram-negative" exact="bacterial" post="endotoxin as the main trigger for systemic inflammatory reaction."/>
 <result pre="caused by gram-negative bacterial endotoxin as the main trigger for" exact="systemic" post="inflammatory reaction. Endotoxin binds to Toll-like receptor 4 (TLR4)"/>
 <result pre="to be effective in the treatment of cytokine storm in" exact="viral" post="infections (SARS-CoV-2). It is possible to suppose that a"/>
 <result pre="be effective in the treatment of cytokine storm in viral" exact="infections" post="(SARS-CoV-2). It is possible to suppose that a clinical"/>
 <result pre="to intervene prior to the initiation of CRS and severe" exact="respiratory" post="distress mainly in patients at high risk of worsening."/>
 <result pre="and current experience of many clinicians. Patients with cytokine release" exact="syndrome" post="secondary to viral etiology, show increased production of pro-inflammatory"/>
 <result pre="current experience of many clinicians. Patients with cytokine release syndrome" exact="secondary" post="to viral etiology, show increased production of pro-inflammatory cytokines"/>
 <result pre="of many clinicians. Patients with cytokine release syndrome secondary to" exact="viral" post="etiology, show increased production of pro-inflammatory cytokines similar to"/>
 <result pre="cytokines similar to that found in patients who develop CRS" exact="secondary" post="to CAR-T cell therapy [29,30]. 2.3.1 Anti TNF-Î± The"/>
 <result pre="Anti IL-6 Tocilizumab remains the most commonly used therapy for" exact="systemic" post="treatment of CRS. Multiple studies conï¬�rmed the correlation of"/>
 <result pre="the most commonly used therapy for systemic treatment of CRS." exact="Multiple" post="studies conï¬�rmed the correlation of peak IL-6 levels with"/>
 <result pre="and safety of tocilizumab in the treatment of SARS-Cov-2 related" exact="pneumonia" post="(TOSCA)â€� (NCT04332913) might show a rationale for those patients"/>
 <result pre="therapy pediatric patients with CD19 expressing relapsed and refractory B-cell" exact="acute lymphoblastic leukemia" post="(NCT02906371). Other molecule which could manage CRS is siltuximab,"/>
 <result pre="pediatric patients with CD19 expressing relapsed and refractory B-cell acute" exact="lymphoblastic leukemia" post="(NCT02906371). Other molecule which could manage CRS is siltuximab,"/>
 <result pre="patients with CD19 expressing relapsed and refractory B-cell acute lymphoblastic" exact="leukemia" post="(NCT02906371). Other molecule which could manage CRS is siltuximab,"/>
 <result pre="According to a survey published by special interest group of" exact="American" post="Society for Blood and Marrow Transplantation Pharmacy, siltuximab should"/>
 <result pre="survey published by special interest group of American Society for" exact="Blood" post="and Marrow Transplantation Pharmacy, siltuximab should be considered for"/>
 <result pre="study of tadekinig-Î±, recombinant human interleukin-18 binding protein (IL-18BP) in" exact="adult-onset Still's disease" post="(Phase II). They concluded that IL-18 inhibition might offer"/>
 <result pre="of tadekinig-Î±, recombinant human interleukin-18 binding protein (IL-18BP) in adult-onset" exact="Still's disease" post="(Phase II). They concluded that IL-18 inhibition might offer"/>
 <result pre="tadekinig-Î±, recombinant human interleukin-18 binding protein (IL-18BP) in adult-onset Still's" exact="disease" post="(Phase II). They concluded that IL-18 inhibition might offer"/>
 <result pre="of therapy within the scope of anti-cytokine treatment such as" exact="NLRC4-related macrophage activation syndrome," post="the etiological factor leading to clinical manifestation of CRS"/>
 <result pre="only in inï¬‚ammatory diseases (rheumatoid arthritis, ulcerative colitis) and in" exact="myeloproliferative disorders" post="(myelofibrosis, polycytaemia vera) but also in the management of"/>
 <result pre="with the JAK1/2 inhibitor ruxolitinib signiï¬�cantly reduced the symptoms of" exact="disease" post="and prolonged survival time in experimental murine model. Ruxolitinib"/>
 <result pre="levels of cytokines in various forms of CRS, not excluding" exact="viral" post="etiology (COVID-19). Although the three candidates have similar JAK"/>
 <result pre="GVHD [43]. At that stage, no information concerning cytokine release" exact="syndrome" post="has been obtained. 2.4 Adjunctive treatment Solitary trials registered"/>
 <result pre="and CXCL10) in H5N1-infected lung cells and reduces migration of" exact="monocyte" post="in experimental model. With its anti-inflammatory effects, it may"/>
 <result pre="current clinical evidence indicates the administration of antioxidants has a" exact="limited" post="effect on cytokine storm and further clinical studies would"/>
 <result pre="used to treat allergic diseases, significantly inhibit degranulation and the" exact="acute" post="release of histamine and inflammatory mediators from mast cells."/>
 <result pre="observed that sodium cromoglycate protects mice effectively from death after" exact="viral infection" post="by alleviating inflammatory injury via its function as an"/>
 <result pre="that sodium cromoglycate protects mice effectively from death after viral" exact="infection" post="by alleviating inflammatory injury via its function as an"/>
 <result pre="so could prevent the cytokine storm in the cases of" exact="viral" post="infections thus becoming an attractive target for immunomodulatory therapy"/>
 <result pre="could prevent the cytokine storm in the cases of viral" exact="infections" post="thus becoming an attractive target for immunomodulatory therapy [55]."/>
 <result pre="attractive target for immunomodulatory therapy [55]. 3 Conclusion Cytokine release" exact="syndrome" post="is a sudden onset of almost life-threatening clinical symptomatology"/>
 <result pre="of almost life-threatening clinical symptomatology which can occur within diverse" exact="external" post="or internal conditions. Early identification of rising state and"/>
 <result pre="immunomodulatory treatment. At present, the most widely used molecule for" exact="systemic" post="treatment of CRS remains tocilizumab. Its FDA and EMA"/>
 <result pre="toxicities: severe side effects of modern targeted and immunotherapy of" exact="cancer" post="and their managementCrit Care.21120178910.1186/s13054-017-1678-128407743 3StrattonK.FordA.RuschE.Wright ClaytonE.Adverse effects of vaccines:"/>
 <result pre="anti-T-cell monoclonal antibody OKT3 in relation to serum levels of" exact="tumor" post="necrosis factor and interferon-gamma [corrected]N Engl J Med3201989142014212785642 5VÃ©ghP.ErdÃ¶sE.BaloghE.JÃ¡nossyT.KovÃ¡tsT.G.A"/>
 <result pre="stem cell transplantationBone Marrow Transplant.306200234735410.1038/sj.bmt.170364012235518 9WilliamsM.KhalidT.HughesS.BonneyD.WynnR.Rituximab-induced Cytokine Storm in the" exact="Absence of" post="Overt Lymphoproliferative DiseaseJ Pediatr Hematol Oncol.3812016e293110.1097/MPH.000000000000048526583621 10WingM.G.MoreauT.GreenwoodJ.SmithR.M.HaleG.Mechanism of first-dose"/>
 <result pre="Overt Lymphoproliferative DiseaseJ Pediatr Hematol Oncol.3812016e293110.1097/MPH.000000000000048526583621 10WingM.G.MoreauT.GreenwoodJ.SmithR.M.HaleG.Mechanism of first-dose cytokine-release" exact="syndrome" post="by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18"/>
 <result pre="in the TGN1412 clinical trial tragedy?Clin Exp Immunol.1623201051652710.1111/j.1365-2249.2010.04264.x20964641 12ZhaoL.YangY.LiW.LiT.GaoQ.Nivolumab-induced cytokine-release" exact="syndrome" post="in relapsed/refractory Hodgkinâ€™s lymphoma: a case report and literature"/>
 <result pre="obinutuzumab and possible relationship with infusion-related reactionsBlood1262420152646264910.1182/blood-2015-09-67080226447188 14AligS.K.DreylingM.SeppiB.AulingerB.WitkowskiL.Severe cytokine release" exact="syndrome" post="after the first dose of Brentuximab Vedotin in a"/>
 <result pre="first dose of Brentuximab Vedotin in a patient with relapsed" exact="systemic" post="anaplastic large cell lymphoma (sALCL): a case report and"/>
 <result pre="dose of Brentuximab Vedotin in a patient with relapsed systemic" exact="anaplastic large cell lymphoma" post="(sALCL): a case report and review of literatureEur J"/>
 <result pre="Vedotin in a patient with relapsed systemic anaplastic large cell" exact="lymphoma" post="(sALCL): a case report and review of literatureEur J"/>
 <result pre="and review of literatureEur J Haematol.946201555455710.1111/ejh.1239624913471 15ToniniG.SantiniD.VincenziB.BorzomatiD.DicuonzoG.Oxaliplatin may induce cytokine-release" exact="syndrome" post="in colorectal cancer patientsJ Biol Regul Homeost Agents.162200210510912144121 16NakamuraN.KanemuraN.ShibataY.MatsumotoT.MabuchiR.Lenalidomide-induced"/>
 <result pre="of literatureEur J Haematol.946201555455710.1111/ejh.1239624913471 15ToniniG.SantiniD.VincenziB.BorzomatiD.DicuonzoG.Oxaliplatin may induce cytokine-release syndrome in" exact="colorectal cancer" post="patientsJ Biol Regul Homeost Agents.162200210510912144121 16NakamuraN.KanemuraN.ShibataY.MatsumotoT.MabuchiR.Lenalidomide-induced cytokine release syndrome"/>
 <result pre="literatureEur J Haematol.946201555455710.1111/ejh.1239624913471 15ToniniG.SantiniD.VincenziB.BorzomatiD.DicuonzoG.Oxaliplatin may induce cytokine-release syndrome in colorectal" exact="cancer" post="patientsJ Biol Regul Homeost Agents.162200210510912144121 16NakamuraN.KanemuraN.ShibataY.MatsumotoT.MabuchiR.Lenalidomide-induced cytokine release syndrome"/>
 <result pre="colorectal cancer patientsJ Biol Regul Homeost Agents.162200210510912144121 16NakamuraN.KanemuraN.ShibataY.MatsumotoT.MabuchiR.Lenalidomide-induced cytokine release" exact="syndrome" post="in a patient with multiple myelomaLeuk Lymphoma55720141691169310.3109/10428194.2013.85330024138307 17Shimabukuro-VornhagenA.GÃ¶delP.SubkleweM.StemmlerH.J.SchlÃ¶ÃŸerH.A.Cytokine release"/>
 <result pre="17Shimabukuro-VornhagenA.GÃ¶delP.SubkleweM.StemmlerH.J.SchlÃ¶ÃŸerH.A.Cytokine release syndromeJ Immunother Cancer.6120185610.1186/s40425-018-0343-929907163 18AikawaN.FujishimaS.ShinozawaY.HoriS.Cytokine-mediated biological response to severe" exact="infections" post="in surgical patientsNihon Geka Gakkai Zasshi97121996105410599032781 19CannaS.W.BehrensE.M.Making sense of"/>
 <result pre="and treating hemophagocytic syndromesPediatr Clin North Am.592201232934410.1016/j.pcl.2012.03.00222560573 20ChungF.Anti-inflammatory cytokines in" exact="asthma" post="and allergy: interleukin-10, interleukin-12, interferon-gammaMediators Inflamm.1022001515910.1080/0962935012005451811405550 21Dâ€™EliaR.V.HarrisonK.OystonP.C.LukaszewskiR.A.ClarkG.C.Targeting the &quot;cytokine"/>
 <result pre="of a new approachPharmacol Rev.552200324126910.1124/pr.55.2.412773629 23PicardM.GalvÃ£oV.R.Current Knowledge and Management of" exact="Hypersensitivity" post="Reactions to Monoclonal AntibodiesJ Allergy Clin Immunol Pract.53201760060910.1016/j.jaip.2016.12.00128110056 24McGonagleD.SharifK.Oâ€™ReganA.BridgewoodC.The"/>
 <result pre="Pract.53201760060910.1016/j.jaip.2016.12.00128110056 24McGonagleD.SharifK.Oâ€™ReganA.BridgewoodC.The Role of Cytokines including Interleukin-6 in COVID-19 induced" exact="Pneumonia" post="and Macrophage Activation Syndrome-Like DiseaseAutoimmun Rev.196202010253710.1016/j.autrev.2020.10253732251717 25ThomsenH.H.RittigN.JohannsenM.MÃ¸llerA.B.JÃ¸rgensenJ.O.Effects of 3-hydroxybutyrate"/>
 <result pre="DiseaseAutoimmun Rev.196202010253710.1016/j.autrev.2020.10253732251717 25ThomsenH.H.RittigN.JohannsenM.MÃ¸llerA.B.JÃ¸rgensenJ.O.Effects of 3-hydroxybutyrate and free fatty acids on" exact="muscle" post="protein kinetics and signaling during LPS-induced inflammation in humans:"/>
 <result pre="cell cytokine release syndromeBr J Haematol.19032020e150e15410.1111/bjh.1696132584416 31SchulertG.S.GromA.A.Pathogenesis of macrophage activation" exact="syndrome" post="and potential for cytokine- directed therapiesAnnu Rev Med.66201514515910.1146/annurev-med-061813-01280625386930 32MurthyH.IqbaM.ChavezJ.C.Kharfan-DabajaM.A.Cytokine"/>
 <result pre="Med.66201514515910.1146/annurev-med-061813-01280625386930 32MurthyH.IqbaM.ChavezJ.C.Kharfan-DabajaM.A.Cytokine Release Syndrome: Current PerspectivesImmunotargets Ther.2982019435210.2147/ITT.S202015 33MahmoudjafariZ.HawksK.G.HsiehA.A.PlescaD.GatwoodK.S.CulosK.A.American Society for" exact="Blood" post="and Marrow Transplantation Pharmacy Special Interest Group Survey on"/>
 <result pre="Administrative, Logistic, and Toxicity Management Practices in the United StatesBiol" exact="Blood" post="Marrow Transplant.2512019263310.1016/j.bbmt.2018.09.02430266675 34RussellB.MossC.GeorgeG.SantaolallaA.CopeA.Associations between immune-suppressive and stimulating drugs and"/>
 <result pre="review of current evidenceEcancermedicalscience.27202020201410.3332/ecancer.2020.10221022 35ShakooryB.CarcilloJ.A.ChathamW.W.AmdurR.L.ZhaoH.Interleukin-1 Receptor Blockade Is Associated With" exact="Reduced" post="Mortality in Sepsis Patients With Features of Macrophage Activation"/>
 <result pre="TrialCrit Care Med.442201627528110.1097/CCM.000000000000140226584195 36TeacheyD.T.LaceyS.F.ShawP.A.MelenhorstJ.J.MaudeS.L.Identification of Predictive Biomarkers for Cytokine Release" exact="Syndrome" post="after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic"/>
 <result pre="Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for" exact="Acute" post="Lymphoblastic LeukemiaCancer Discov.66201666467910.1158/2159-8290.CD-16-004027076371 37FedericiS.MartiniA.GattornoM.The Central Role of Anti-IL-1 Blockade"/>
 <result pre="Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute" exact="Lymphoblastic" post="LeukemiaCancer Discov.66201666467910.1158/2159-8290.CD-16-004027076371 37FedericiS.MartiniA.GattornoM.The Central Role of Anti-IL-1 Blockade in"/>
 <result pre="Antigen Receptor T-cell Therapy for Acute Lymphoblastic LeukemiaCancer Discov.66201666467910.1158/2159-8290.CD-16-004027076371 37FedericiS.MartiniA.GattornoM.The" exact="Central" post="Role of Anti-IL-1 Blockade in the Treatment of Monogenic"/>
 <result pre="target of JAK2 inhibitor FedratinibJ Microbiol Immunol Infect.11202010.1016/j.jmii.2020.03.005S1684-1182(20)30065-30067 40AhmedA.MerrillS.A.AlsawahF.BockenstedtP.CampagnaroE.Ruxolitinib in" exact="adult" post="patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot"/>
 <result pre="inhibitor FedratinibJ Microbiol Immunol Infect.11202010.1016/j.jmii.2020.03.005S1684-1182(20)30065-30067 40AhmedA.MerrillS.A.AlsawahF.BockenstedtP.CampagnaroE.Ruxolitinib in adult patients with" exact="secondary" post="haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trialLancet Haematol.6122019e630e63710.1016/S2352-3026(19)30156-531537486 41DasR.GuanP.SpragueL.VerbistK.TedrickP.Janus"/>
 <result pre="pilot trialLancet Haematol.6122019e630e63710.1016/S2352-3026(19)30156-531537486 41DasR.GuanP.SpragueL.VerbistK.TedrickP.Janus kinase inhibition lessens inflammation and ameliorates" exact="disease" post="in murine models of hemophagocytic lymphohistiocytosisBlood.1271320161666167510.1182/blood-2015-12-684399(2016)26825707 42StebbingJ.PhelanA.GriffinI.TuckerC.OechsleO.COVID-19: combining antiviral"/>
 <result pre="trial of itacitinib, a selective JAK1 inhibitor, in patients with" exact="acute" post="graft-versus-host diseaseBlood Adv.28820201656166910.1182/bloodadvances.2019001043(2020) 44GeilerJ.MichaelisM.NaczkP.LeutzA.LangerK.N-acetyl-L-cysteine (NAC) inhibits virus replication and"/>
 <result pre="of erdosteine and N-acetylcysteine on apoptotic and antiapoptotic markers in" exact="pulmonary" post="epithelial cells in sepsisEurasian J Med.453201316717510.5152/eajm.2013.3525610275 47LiuQ.ZhouY.H.YangZ.Q.The cytokine storm"/>
 <result pre="erdosteine and N-acetylcysteine on apoptotic and antiapoptotic markers in pulmonary" exact="epithelial" post="cells in sepsisEurasian J Med.453201316717510.5152/eajm.2013.3525610275 47LiuQ.ZhouY.H.YangZ.Q.The cytokine storm of"/>
 <result pre="Covid-19N Engl J Med.7202010.1056/NEJMoa2012410NEJMoa2012410 51HeG.LiQ.LiW.RuanY.XiongX.Effect of ulinastatin on interleukins and" exact="pulmonary" post="function in bypass patients: a meta-analysis of randomized controlled"/>
 <result pre="in vitro anti-inflammatory and immunomodulatory properties to clinical practice in" exact="respiratory" post="diseasesEur J Clin Pharmacol.685201247950310.1007/s00228-011-1161-x22105373 53CecrdlovaE.PetrickovaK.KolesarL.PetricekM.SekerkovaA.Manumycin A downregulates release of"/>
</results>
